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A Ab bs st tr ra ac ct t   
B Ba ac ck kg gr ro ou un nd d. . A substantial minority of individuals who initially apply for genetic counselling for breast/ovarian
cancer withdraw at an early stage from the counselling process. This study investigated the self-reported reasons
for early withdrawal and the factors associated significantly with such withdrawal. 
M Me et th ho od ds s. . Self-report questionnaires were mailed to 83 women who had applied for genetic counselling for
breast/ovarian cancer but who subsequently withdrew from the counselling process (the ”withdrawers”).
A comparison group of 105 women who had completed the genetic counselling (the ”attendees”) received
a similar questionnaire. The questionnaire assessed sociodemographic characteristics, reasons for applying for
genetic counselling, general distress (MHI-5), cancer-specific distress (IES), and cancer worries. For those women
who discontinued the counselling, reasons for withdrawal were also assessed. 
R Re es su ul lt ts s. . The primary reasons given for withdrawing from counselling were difficulties in anticipating the consequences
of genetic counselling (28%), and worries about being unable to adequately cope with an unfavourable test result
(20%). Compared to the attendees, the withdrawers were significantly younger, more frequently asymptomatic,
more often the first and only member of the family to apply for counselling, and less worried about cancer. Current
levels of cancer-specific distress and general distress were comparable between the two groups. 
C Co on nc cl lu us si io on n. . Younger women, those without a history of cancer, and those who are first in their family to apply
are more likely to withdraw prematurely from genetic counselling for breast/ovarian cancer. These withdrawers
have no elevated levels of distress. However, a substantial percentage of individuals discontinue counselling
due to concerns about their (in)ability to cope with a possible unfavourable test outcome. This suggests that
greater attention should be paid to ways of coping with test results during the very first contact with the clinic. 
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I In nt tr ro od du uc ct ti io on n
Localization of the two breast cancer susceptibility
genes, BRCA1 and BRCA2, has enabled mutation
detection techniques to be used for individuals who
wish to learn whether or not they are at risk of being
a mutation  carrier  [1,  2].  While  the  majority  of
individuals who apply for genetic counselling and
testing go forward with the procedure, a substantial
minority do not follow through or withdraw from
counselling at an early stage. For example, over
a period of 4.5 years (from April 1995 to DecemberH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 20
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T Ta ab bl le e   1 1. .   S So oc ci io od de em mo og gr ra ap ph hi ic c   a an nd d   m me ed di ic ca al l   c ch ha ar ra ac ct te er ri is st ti ic cs s   o of f   t th he e   w wi it th hd dr ra aw we er rs s   ( (n n= =4 48 8) )   a an nd d   t th he e   a at tt te en nd de ee es s   ( (n n= =8 85 5) )   
w wi it th hd dr ra aw we er rs s   ( (n n= =4 48 8) )    a at tt te en nd de ee es s   ( (n n= =8 85 5) )    p p- -v va al lu ue e
n n % % n n % %
Age (mean, sd) in years [range] mean=44 [20-74] (sd=11)  mean=50 [26-78]  (sd=12)  p=0.003
Marital status
– living with a partner/married  37 77% 62 73% p=0.60
Children
– yes 32 67% 67 79% p=0.12
Education
– low  11 24% 23 27%
– moderate  16 35% 39 46% p=0.20
– high  16 41% 22 26%
Treated for cancer
– yes 21 44% 61 72% p=0.001
Role in family 
– first who applied 41 85% 35 41%
– first, with relative(s)  2 4% 38 45% p=0.000
– others applied first 5 10% 12 14%
1999), approximately 1,700 individuals contacted the
Family Cancer Clinic of the Netherlands Cancer
Institute and requested for genetic counselling. Of these
1,700 individuals, approximately two-thirds actually
underwent genetic counselling, with or without genetic
testing. However, the remaining one-third did not follow
through with a clinic appointment. 
The three most commonly reported reasons for
initiating genetic counselling and/or testing for cancer
are the desire to obtain a greater degree of certainty
about personal cancer risk, to estimate the risk of cancer
for one’s children or other family members [3-7], and
to obtain information on possible strategies for reducing
the risk of developing cancer [6-8]. Other motives
reported in the literature include family planning and
a desire to contribute to scientific research [3, 4, 7]. 
It is unclear whether the initial motives of those who
ultimately choose not to go forward with genetic
counselling are different from those who actually do so. 
Only a few studies have investigated the reasons
why some individuals do not carry through after their
initial application for genetic testing. Geer et al [9]
reported that concerns about health insurance (41%),
cost of the genetic counselling and testing (32%), the
emotional impact of the process on oneself or one’s
family (30%), low anticipated benefit (30%), and time
commitment (24%) were the most frequently stated
reasons for early withdrawal from genetic counselling
for cancer. Other studies conducted in the U. S. confirm
that concern about discrimination by health insurers
plays a particularly important role in non-participation
in genetic testing [3, 10], despite the fact that such fear
is reported to greatly exceed actual discrimination
practices [11]. Armstrong et al [12] found that those
who declined genetic testing for cancer were less likely
to consider it important to obtain information about
their  personal  cancer  risk  or  to  provide  such
information to family members, and more frequently
reported being concerned about consequences for
health insurance than those who underwent testing. 
Relatively little information is available on this
subject from countries other than the U.S. In a recent
study among 27 relatives from families in the UK with
a known BRCA1/2 mutation who declined testing, the
major barriers to testing included ”apprehension about
the result” (74%), ”travelling to the genetics clinic”
(33%) and ”taking time away from work/family” (30%)
[13]. Additional issues that may negatively impact
genetic clinic attendance include ambiguity in the
invitation to attend the clinic, and dissatisfaction with
the initial contact(s) with the clinic.
Studies of the possible association between levels of
psychological distress and (non-)attendance or early
withdrawal from genetic counselling and testing have
yielded somewhat inconsistent results. In their study
among women from families with a proven BRCA1/2
mutation, Lerman et al [14] found that the presence of
cancer-related stress symptoms before genetic testing
was strongly predictive of the onset of depressive
symptoms in family members who were invited but
declined testing. These non-attendees also experienced
significantly higher levels of depression than women whoH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 21
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had gone forward with testing (regardless of the test
results). A recent small Dutch study [15] described
attitudes and distress levels among 13 women at 25%
or 50% risk of being a BRCA1/2 mutation carrier, who
declined genetic testing. Four women (31%) reported
feeling  emotionally  unprepared  to  cope  with  the
consequences  of  testing;  however,  no  significant
differences were found in mean distress levels between
these women and a comparison group composed of
women  who  had  undergone  genetic  testing.
Valdimarsdottir et al [16] reported that women with
a previous history of breast cancer who had high or low
levels of anxiety declined genetic counselling more
frequently than women with intermediate levels of anxiety.
Foster et al [13] reported that female test decliners had
significantly lower levels of cancer worries than the
female test acceptors. Other studies have also reported
a positive relationship between cancer-specific distress
and participation in BRCA1/2 counselling and/or testing
(i.e. higher participation rates among those with higher
levels of cancer-specific distress) [17, 18]. 
A final factor that may play a role in early withdrawal
from genetic counselling is the timing of an individual’s
contact with the clinic in relation to that of other family
members. That is, those who are the first in their family
to undergo genetic counselling may have a more
difficult task than those who request genetic counselling
after other family members have completed the process
[19]. One could also hypothesize that the ”first utilizers”
of genetic counselling in a family may be those who
are more likely to withdraw early from the process due
to family-related stress. There are currently no empirical
data available to inform on this latter issue. 
The present study was undertaken to investigate the
self-reported reasons for early withdrawal from cancer
genetic counselling/testing in the Dutch setting, and
to determine which sociodemographic, clinical and
psychosocial factors are significantly associated with
such withdrawal. 
M Me et th ho od ds s   
S St tu ud dy y  s se et tt ti in ng g  a an nd d  s st ta an nd da ar rd d  c cl li in ni ic c  p pr ro oc ce ed du ur re es s
The study was conducted at the Family Cancer
Clinic  of  the  Netherlands  Cancer  Institute  in
Amsterdam, the Netherlands. At this clinic, individuals
requesting genetic counselling typically do so initially
by telephone. A brief risk assessment is made by the
genetic nurse to determine the appropriateness of the
request.  If  applicable,  individuals  then  receive
a ”family form” to be completed before the first visit
to the clinic. The purpose of this form is to obtain
a full description of the cancer history of all first
degree, second degree and, if possible, third degree
family members. During the initial face-to-face intake
session at the clinic, a family tree is drawn and
information is provided about the possibilities and
limitations of genetic testing. Between 6 weeks and
3 months following this initial visit (once medical data
on relatives have been obtained, and diagnoses
confirmed) a second consultation takes place at the
clinic during which details of the family are discussed,
and the attitude of the counselee (and his/her partner)
towards genetic testing is explored. DNA testing is
then offered, when appropriate. The results of the
T Ta ab bl le e   2 2. .   M Mo os st t   i im mp po or rt ta an nt t   r re ea as so on ns s   t to o   r re eq qu ue es st t   g ge en ne et ti ic c   c co ou un ns se el ll li in ng g   f fo or r   t th he e   f fa am mi il li ia al l   o oc cc cu ur rr re en nc ce e   o of f   b br re ea as st t/ /o ov va ar ri ia an n   c ca an nc ce er r: :   d di if ff fe er re en nc ce es s   b be et tw we ee en n
t th he e   w wi it th hd dr ra aw we er rs s   ( (n n= =4 48 8) )   a an nd d   t th he e   a at tt te en nd de ee es s   ( (n n= =8 85 5) )   
w wi it th hd dr ra aw we er rs s a at tt te en nd de ee es s χ χ
2 2
n n % % n n % % p p- -v va al lu ue e
to obtain certainty 29 60 32 38 0.01
to be able to take preventive actions 23 48 49 48 0.97
to estimate the risk for my children 17 35 51 60 0.01
to help science 6 13 10 12 0.90
worried about cancer (recurrence)  12 25 24 28 0.69
requested by a family member 3 6 19 22 0.02
referred by a physician 11 23 11 13 0.14
general planning for the future 2 4 0 – [0.06]
family planning 1 2 4 5 0.45H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 22
Eveline Bleiker et al
DNA testing are made available between 6 weeks (in
those cases where a gene mutation in the family is
already known) and approximately 6 months after the
blood sample is taken. The results are conveyed to
the counselee(s) in a face-to-face consultation. The
counselling program is described in great detail
elsewhere [4]. 
S St tu ud dy y  s sa am mp pl le e  a an nd d  p pr ro oc ce ed du ur re es s
The study sample comprised two groups: (1) women
who requested genetic counselling for breast and/or
ovarian cancer but ultimately did not carry through with
the process (hereafter referred to as ”withdrawers”);
and  (2)  women  who,  during  the  same  period,
requested genetic counselling for breast and/or ovarian
cancer and completed the counselling process. 
T Th he e   ” ”w wi it th hd dr ra aw we er r” ”   s sa am mp pl le e. . The withdrawer sample
was composed of women who requested genetic
counselling for breast/ovarian cancer at the Family
Cancer Clinic of the Netherlands Cancer Institute
between January 1999 and March 2000, who either
had a telephone contact with the clinic but did not
follow through with a clinic appointment, or had
attended once but had not returned for a second
session during the subsequent 12-month period. 
All  eligible  women  received  a self-report
questionnaire, on average, 18 months (median 17, SD
4 months) after their application for genetic counselling.
Those who had not responded to the questionnaire
within 3 weeks were sent a reminder letter together with
a copy of the questionnaire. 
T Th he e   ” ”a at tt te en nd de ee e” ”   s sa am mp pl le e. . A comparison group was
composed of women who had initiated genetic
counselling at the same clinic during the same time
period  as  the  withdrawer  group,  but  had
subsequently completed the counselling process.
These women were participating in a parallel study
of the psychosocial impact of genetic counselling.
They  completed  a self-report  questionnaire
approximately  one  month  after  their  final
appointment at the clinic; this was, on average,
8 months (median 7, SD 5 months) after their first
visit  to  the  clinic.  Those  women  who  had  not
responded to this questionnaire within 3 weeks were
sent a reminder letter together with a copy of the
questionnaire.  The  study  was  approved  by  the
institutional review board of the hospital. 
T Ta ab bl le e   3 3. .   M Mo os st t   i im mp po or rt ta an nt t   r re ea as so on ns s   g gi iv ve en n   f fo or r   w wi it th hd dr ra aw wa al l   f fr ro om m   g ge en ne et ti ic c   c co ou un ns se el ll li in ng g   b by y   t th he e   g gr ro ou up p   o of f   n no on n- -a at tt te en nd de ee es s   ( (n n= =4 46 6) )   
n n % %
It is difficult to anticipate the consequences of genetic counselling 13 28
I am worried that I will not cope well with an unfavourable test result 9 20
I do not have sufficient information about cancer in my family 9 20
I want to postpone the genetic counselling for some years 9 20
I am worried that genetic counselling may cause stress in my immediate relationship/family (partner/children)  8 17
I am not interested in genetic counselling at the moment, it has low priority 6 13
The subject ”cancer and hereditary” is too emotional/burdensome 6  13
One or more relatives do not want to participate in the genetic inquiries/counselling 4 9
I am worried about possible consequences for obtaining a mortgage or life insurance 4 9
I am worried that genetic counselling may cause stress within my larger family (brothers/sisters/cousins/parents, etc.)  4 9
I am worried about the possible consequences for my future plans (starting a relationship, choice of job, wish for children)  4 9
I am still waiting for an invitation from the family cancer clinic 3 7
I do not expect that genetic counselling will bring much news for me 2 4
I will wait for the results from other family members before I proceed with genetic counselling 1 2
Others advised me against the genetic counselling 1 2
I have had bad experiences with the family cancer clinic 0 0H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 23
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Q Qu ue es st ti io on nn na ai ir re e  c co on nt te en nt t
S So oc ci io od de em mo og gr ra ap ph hi ic c   a an nd d   m me ed di ic ca al l   v va ar ri ia ab bl le es s included
age, education, marital status, number of children,
previous history of cancer, role in the family with regard
to genetic counselling (i.e. first and only applicant; first
applicant  together  with  other  family  members;
secondary applicant). 
R Re ea as so on ns s   f fo or r   s se ee ek ki in ng g   g ge en ne et ti ic c   c co ou un ns se el ll li in ng g: : Based on
previous studies [4, 20] a list of possible reasons for
undergoing  genetic  counselling  was  presented.
Respondents  were  asked  to  indicate  the  3 most
important reasons why they had sought counselling. 
G Ge en ne er ra al l    d di is st tr re es ss s, ,    c ca an nc ce er r- -s sp pe ec ci if fi ic c    d di is st tr re es ss s, ,    a an nd d
c ca an nc ce er r   w wo or rr ri ie es s: : General psychological distress was
assessed with the Mental Health Index-5 (MHI-5),
a subscale of the SF-36 Health Survey [21, 22].
Cancer-specific distress was assessed with the subscale
”intrusive thoughts” of the Impact of Event scale (IES)
[23, 24]. In the present study, the questions focused
on the extent of intrusive thoughts about the familial
occurrence of cancer. The IES has been used previously
in the context of genetic counselling [14, 25]. Cancer
worries were assessed with an adapted version of the
4-item cancer-worry scale of Lerman et al [26]. This
scale assesses the frequency of worries during the
previous 4-week period about one’s own cancer risk
and the risk of cancer among family members, and the
impact of such worries on mood, and daily functioning. 
R Re ea as so on ns s    f fo or r    w wi it th hd dr ra aw wi in ng g    f fr ro om m    t th he e    g ge en ne et ti ic c
c co ou un ns se el ll li in ng g: :   Those women who had withdrawn from
the genetic counselling process were asked to select
from a pre-set list those factors that had played a part
in their decision to withdraw. They could also add
additional reasons not included in the list (for the items,
see Table 3). 
I In nt te en nt ti io on n    t to o    c co on nt ti in nu ue e    g ge en ne et ti ic c    c co ou un ns se el ll li in ng g was
assessed with a single question: ”Do you intend to
continue genetic counselling at some time in the
future?” The response categories were adapted from
those used by Jacobsen et al [27]: 1) no, certainly not;
2) no, not yet; 3) yes, sometime in the future (after more
than one year); 4) yes, within one year; 5) yes, I have
just continued; or 6) I don’t know. 
S St ta at ti is st ti ic ca al l  a an na al ly ys si is s
Student’s t-tests and chi-square tests were used to
make comparisons between the withdrawers and
attendees at the univariate level. Logistic regression
analysis was used to identify those variables most
strongly associated with (non-)participation in the
genetic counselling at the multivariate level. 
R Re es su ul lt ts s
R Re es sp po on ns se e  r ra at te es s
R Re es sp po on ns se e   o of f   t th he e   w wi it th hd dr ra aw wa al l   s sa am mp pl le e: :   In total, 83
women were identified as being withdrawers. However,
10 of the women were subsequently excluded from the
study sample for the following reasons: 5 women
reported that they had continued counselling in another
clinic; 2 women learned that their sister, who had
undergone  genetic  counselling,  had  received  an
inconclusive test result and consequently genetic testing
was no longer indicated; 1 woman was told at intake
that she was at low risk and therefore counselling was
not necessary; 1 woman died; and 1 woman moved
to an unknown address. Of the remaining 73 eligible
women, 48 (66%) returned the questionnaire. Of these
48 respondents, 36 had had a telephone intake only
and 12 had participated in one face-to-face intake;
none had had any further contact with the clinic for at
least 12 months following their initial contact. 
R Re es sp po on ns se e   o of f   t th he e   a at tt te en nd de ee es s: :   In total, 105 women
who completed their genetic counselling for breast
and/or ovarian cancer were invited to participate in
the study. Of these, 85 women (81%) completed and
returned the questionnaire. Of these 85 women, 15
were found to be a carrier of a BRCA1/2 mutation,
6 were proven to be a non-carrier, and the remainder
had an inconclusive DNA test result (n=62) or did not
undergo DNA testing (n=2). 
S So oc ci io od de em mo og gr ra ap ph hi ic c  a an nd d  c cl li in ni ic ca al l  c ch ha ar ra ac ct te er ri is st ti ic cs s  
o of f  w wi it th hd dr ra aw we er rs s  v ve er rs su us s  a at tt te en nd de ee es s
Compared with the attendees, the withdrawers were
significantly younger (mean=44 vs. 50 years; p=0.003),
more frequently asymptomatic (44% vs. 61%; p=0.001),
and more frequently the first and sole individual in their
family to have applied for genetic counselling (85% vs.
41%; p<0.000) (Table 1). No statistically significant
differences were found between the two groups for
education, marital status, or having children. 
S Se el lf f- -r re ep po or rt te ed d  r re ea as so on ns s  f fo or r  r re eq qu ue es st ti in ng g  g ge en ne et ti ic c  c co ou un ns se el ll li in ng g
Both the withdrawer and attendee groups indicated
that three most important reasons to undergo the
genetic counselling were to obtain certainty, to be able
to take preventive actions, and to estimate the cancer
risk for their children (Table 2). However, the withdrawers
were more likely to report obtaining certainty for
themselves as the primary reason for seeking counselling
(60%  vs.  38%,  p=0.01),  whereas  the  attendees.
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indicated estimating the risk for their children most
frequently (60% vs. 35%, p=0.01). Approximately
one-quarter of the respondents in both groups indicated
that being worried about cancer (recurrence) was
a major reason for seeking counselling. Those who
withdrew from counselling were significantly less likely
to have attended the clinic upon request of a family
member than were those who continued with the
counselling process (6% vs. 22%, p=0.02). 
S Se el lf f- -r re ep po or rt te ed d  r re ea as so on ns s  f fo or r  w wi it th hd dr ra aw wi in ng g  
f fr ro om m  g ge en ne et ti ic c  c co ou un ns se el ll li in ng g
Of the women who withdrew from genetic counselling
28% indicated that they found it difficult to anticipate the
consequences of the counselling, 20% were worried that
they could not handle an unfavourable genetic test result,
and 20% believed that they had insufficient information
about the occurrence of cancer in their family to merit
continued counselling (Table 3). 17% of the respondents
were worried that the genetic counselling might cause
stress in their relationship with their partner or children,
and 9% were worried about such problems with their
extended family (parents, brothers, sisters, cousins, etc.).
Another 9% were worried about possible discrimination
in obtaining a mortgage or life insurance, and 9% were
concerned about the possible consequences for future
plans such as starting a relationship, starting a family, or
pursuing  a career.  None  of  the  women  reported
dissatisfaction with the quality of the genetic counselling
service  as  a reason  for  withdrawing.  Interestingly,
3 women indicated that they had not continued the
counselling because they were still waiting for an invitation
from the clinic to do so (after more than 1 year). 
Of the 48 women who withdrew, 48% planned to
continue the genetic counselling in the future: 4 women
had recently made an appointment with the clinic, 10
intended to make an appointment within 1 year, and
9 planned to make an appointment sometime in the
future. Only 1 woman was convinced that she did not
want further counselling, 3 had no definite plans, and
14 were undecided. Seven women gave other answers
such as: ”I would like to discuss this with my physician
before taking any steps”; ”I would like to continue the
counselling, but only if I don’t have to complete the
family history form”. 
C Cu ur rr re en nt t  l le ev ve el ls s  o of f  p ps sy yc ch ho ol lo og gi ic ca al l  d di is st tr re es ss s  
There were no statistically significant differences
between the withdrawers and the attendees in the
mean scores for general distress (MHI-5). Moreover,
the mean scores of both groups were comparable to
normative data of Dutch women from the general
population (aged 20-78 years) [22]. 
T Ta ab bl le e   4 4. .   D Da at ta a   o on n   g ge en ne er ra al l   d di is st tr re es ss s   ( (M MH HI I- -5 5) ), ,   c ca an nc ce er r- -s sp pe ec ci if fi ic c   d di is st tr re es ss s   ( (I IE ES S) ), ,   a an nd d   c ca an nc ce er r   w wo or rr ri ie es s   
W Wi it th hd dr ra aw we er rs s   ( (n n= =4 47 7) )    A At tt te en nd de ee es s   ( (n n= =8 82 2) )    p p- -v va al lu ue e   
M Me ea an n   ( (s sd d) )    n n % % M Me ea an n   ( (s sd d) )    n n % %
G Ge en ne er ra al l   d di is st tr re es ss s   ( (M MH HI I- -5 5) )* *    74 (15)  72 (15)  p=0.39
– low (≤59)  7 15% 17 21%
– moderate (60-80)  24 51% 39 48% p=0.71
– high (≥81)  16 34% 26 32%
C Ca an nc ce er r- -s sp pe ec ci if fi ic c   d di is st tr re es ss s   ( (I IE ES S) )* ** *    7.8 (7.5)  10.2 (8.4)  p=0.12
– low (≤8)  25 58% 34 45%
– moderate (9-19)  13 30% 30 40% p=0.37
– high (≥20)  5 12% 12 16%
C Ca an nc ce er r   w wo or rr ri ie es s* ** * 5.9 (2.1)  7.3 (2.2)  p<0.000
– few/none (≥5)  30 64% 18 23%
– some (6-8)  10 21% 38 49% p<0.000
– frequently (≥9)  7 15% 22 28%
* high scores indicate low distress (or high mental health)
** high scores indicate high distressH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 25
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No statistically significant differences were observed
between withdrawers and attendees in mean levels of
intrusive thoughts (IES scores), or in the percentage
with clinically relevant levels of such thoughts (scores
>20; 12% vs. 16%, p=0.37). 
Women from the withdrawer group experienced,
on average, significantly fewer worries about cancer
during  the  previous  4 weeks  compared  with  the
attendees (p<0.001) (Table 4). This was evidenced
both when analysing cancer worries as a continuous
variable,  and  when  categorizing  the  scale  into
”few/none” versus ”some” versus ”frequent” worries. 
D Di is sc cu us ss si io on n   
This study was undertaken to investigate the self-
reported reasons for discontinuation of the genetic
counselling process for breast/ovarian cancer, and to
determine which factors are significantly associated with
such withdrawal. The results suggest that those women
who withdraw from genetic counselling are more likely
to have applied for counselling out of concern about
their own cancer risk, rather than that of their children.
A similar  finding  has  been  reported  earlier  [12].
Conversely, those who continued counselling were more
likely to have had cancer, and thus may have been less
concerned about their own cancer risk than that of their
children or other family members. Social network
influences also appear to play a role in the decision to
(dis)continue genetic counselling, as those who withdrew
from the process were less likely than those who
continued to have been prompted by family members
to seek counselling in the first place. 
Although  the  self-reported  reasons  for  early
discontinuation of genetic counselling were diverse, the
main reasons cited were of a psychosocial nature,
including difficulties in anticipating the consequences of
genetic counselling, worries about not being able to cope
well with an unfavourable test result, and concerns that
the counselling process might create stress in the family.
As also reported by Lodder et al [15], most withdrawers
seemed to have thoroughly reflected on their own
decision not to undergo genetic counselling. In contrast
to studies emanating from the U.S. [3, 10, 11], relatively
few women indicated that fear of insurance or job
discrimination contributed significantly to their decision
not to go forward with genetic counselling and testing. 
We  were  concerned  that  those  who  withdrew
prematurely from the counselling process might report
high levels of distress at follow-up. However, this was
not found to be the case. Current levels of both general
and cancer-specific distress were comparable to those
who  continued  with  the  counselling.  Moreover,
withdrawers reported significantly fewer cancer worries
than the attendees. Similar findings have been reported
by Foster et al [13]. 
Several possible limitations of the study merit
mentioning. First, although the overall response rate
of 75% is quite respectable for this type of survey
research, higher levels of non-response were observed
in the withdrawer group than in the attendee group
(66% vs. 81%). One cannot rule out the possibility that
those women who chose not to complete our survey
may have differed from the participants in their self-
reported motives for initiating genetic counselling, and
in their current levels of psychological distress. We
would also note that our study sample was restricted
to those women who had sufficient interest, at least
initially, in genetic counselling to contact the family
cancer clinic. The results cannot be generalized to the
broader population of high-risk women who have never
had  contact  with  a family  cancer  clinic.  This  is
a separate but important population of women that
deserves additional research attention. 
Given the cross-sectional retrospective study design,
it was not possible to determine whether levels of
psychological distress at the time of the initial contact
with  the  family  cancer  clinic  were  associated
significantly with the decision to withdraw from the
counselling process. We would emphasize that our
results regarding current levels of psychological distress
cannot be compared with those reported by Lerman et
al [14] and Valdimarsddottir et al [16] in that, in these
latter studies, distress levels were assessed prior to the
decision to continue or discontinue counselling. 
Finally, we would note that our data are based
primarily on self-reported attitudes and behaviour. Thus,
for example, we assessed the behavioural intentions of
those women who had withdrawn from counselling.
Interestingly, of the 23 withdrawers who indicated that
they intended to restart the genetic counselling at some
later date, only 8 had done so at the time that this report
was being written (approximately 3 years later). This
would suggest that the withdrawals that we observed
most often reflected a final decision, rather than
postponement of counselling. 
C Cl li in ni ic ca al l  r re el le ev va an nc ce e  o of f  t th he e  s st tu ud dy y  
The primary objective of this study was to better
understand the reasons why clients withdraw prematurely
from genetic counselling, and to determine if such
withdrawal is related significantly to the sociodemo-
graphic, psychosocial or clinical characteristics of the
individual, or to factors related to the counselling services
themselves. 
The results suggest that there is little reason to be
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distress among early withdrawers. Levels of self-
reported  distress  were  comparable  between  the
withdrawer and attendee groups, and the withdrawers
actually reported significantly fewer cancer worries than
the attendees. Nevertheless, we would note that
concerns about not being able to anticipate the
consequences of genetic counselling and worries about
not being able to cope well with an unfavourable DNA
test result were important self-reported reasons for
discontinuing the counselling. This suggests the need
to devote greater attention early in the counselling
process to discussing both the possible consequences
of the counselling process and outcome, and in
evaluating individual client’s concerns about their
ability to cope with negative outcomes. 
The results also suggest that younger attendees,
those without a history of breast cancer, and those who
are the first in their family to request genetic counselling
are at greatest risk of early withdrawal. Previous studies
have demonstrated the value of shared responsibility
within families seeking genetic counselling [19], and
thus it may be important to encourage individuals who
apply for such counselling to engage other family
members in the process. Finally, we observed that the
majority of those who withdraw from the counselling
did so following an initial telephone contact, but before
they had had a face-to-face information/education
session  during  which  the  nature  and  possible
consequences  of  genetic  counselling  could  be
discussed in greater detail. We would recommend that
clinic intake procedures be designed in such a way
that encourage deferring the decision about whether
or not to go forward with counselling and testing until
such a face-to-face session has taken place. In this
way, potential clients will be in a better position to make
a more informed and balanced decision about whether
to continue to receive counselling and potentially to
undergo genetic testing, and whether this might be
appropriate for other family members as well. 
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